It is difficult to rise above the chatter these days. The Internet gives people unfettered access to all the information that’s ever existed in the world. So how are they ever supposed to navigate through this vast sea of information to get the products that they want?
This conundrum has had many tech companies reaching out to a news magazine program called NewsWatch TV. The program centers around breaking news as well as emerging news in technology. The program is aired in over 200 markets worldwide and has the potential reach of about 95 million households.
NewsWatch TV can connect tech companies with eager tech-savvy customers. That’s because the people who are watching the program are already interested in technology. This gives any tech company looking to spread the word about their latest innovations a captive audience.
There are all sorts of testimonials to the effectiveness of this exposure. Steelseries is a headphone company that began working with NewsWatch TV some time ago. The company’s senior director of marketing says that working with NewsWatch TV was a dream. She continues on to say that the staff at NewsWatch TV has a deep and comprehensive understanding of PR. She also says that the NewsWatch TV helped make her technological gadgets understandable to the consumer during their news bits.
Both the Saygus Smartphone Company and the Avanca Company exceeded fundraising goals using the services of NewsWatch TV. The television news program aired news segments about each of these tech companies concurrently with the companies’ fundraising campaigns. Each of the companies shot right past their fundraising goals. The Avanca Company raised nearly $500,000 after setting the bar at just $10,000. The Saygus Smartphone Company was even more successful. The tech company was able to raise $1.3 million to exceed the goal of $300,000.
Seattle Genetics has been active in studying human antibodies since it was established in 1998. The company has also been manipulating antibodies and packaging them into drugs since then. The company’s great performance is as a result of linking therapy to antibodies. The company uses antibodies to develop toxins that destroy cancer cells. This strategy could make Seattle Genetics one of the leading companies globally in the health sector.
Seattle genetics offers employment opportunities to about 900 people. The company’s market value is approximately $10 billion. Seattle Genetics is currently considered the leading biotech firm in Washington. The company still aims at becoming an international pharmaceutical firm. Seattle Genetics spends a significant amount of money in marketing and research activities. The company also aims at increasing the number of employees.
Seattle Genetics’ flagship drug known as Adcetric is quite effective at treating Hodgkin lymphoma.With the tests proving that the drug works, it is expected that sales of Adcetric could begin anytime soon. Clay Siegall said that the company is one of the upcoming multiproduct and oncology companies. Clay refers to the company’s long list of drugs to demonstrate the company’s achievements and his unmatched commitment to continue building the company. Clay says that the firm does not plan to sell to other companies.
Clay also shows his commitment to drug development by moving beyond the general focus of biotech firms. After partnering with Takeda, Seattle Genetics discovered its potential and went ahead to open a branch in Switzerland to expand its customer base. Seattle Genetics is currently experiencing tremendous growth. For instance, in 2016, the company generated about $418 million. The company’s stock has tripled in less than five years. Analysts state that the rising value of the company increasing the chances of a future buyout. Due to the high ambitions of the company, its research spending in 2016 was $376 million.
Clay Siegall played a significant role in founding Seattle Genetics. Currently, Mr. Clay serves in various executive positions in the company. At Seattle Genetics, Clay is the Chairman, President, and CEO. Under Clay’s outstanding leadership, the company has developed several cancer therapies based on antibodies. One of its successful projects was the development of Adcentris which was approved by the Food and Drug Administration of the United States. Currently, Clay Siegall is a board member of Alder BioPharmaceuticals which is privately owned. Clay Siegall also holds 15 patents.